Weitere Kapitel dieses Buchs durch Wischen aufrufen
The national epidemic of addiction to and overdose from opioids is the worst public health crisis the United States has faced in decades. The health care system is critical to the public policy response, both because of the services it can provide people with opioid use disorder and the changes in clinical practice it must make to prevent new cases of addiction. For historical and cultural reasons, health services for people with opioid use disorder are often of uneven quality and poorly integrated with the rest of health care. However, effective services are available that can make a major contribution to pushing back against the epidemic. These include opioid agonist therapies (e.g., buprenorphine maintenance), antagonist therapies (e.g., extended-release naltrexone), and psychosocial treatments. Interventions that reduce the mortality and morbidity risks of opioids, such as syringe exchange and naloxone provision, are also critical to an effective public health response. Supply-side policies within the US health care system are also essential because overprescribing is at an extraordinarily high level both historically and currently in comparison to other nations. A range of monitoring, educational, and incentive-based interventions show promise of returning the United States to a more rational prescribing pattern.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:
Ruhm, C. J. (2018). Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999–2015. Addiction, 113, 1339–1344. CrossRef
Katz, J. (2017, September 2). The first count of fentanyl deaths in 2016: Up 540% in three years. New York Times. https://www.nytimes.com/interactive/2017/09/02/upshot/fentanyl-drug-overdose-deaths.html.
Humphreys, K., Caulkins, J., & Felbab-Brown, V. (2018). Opioids of the masses: Stopping an American epidemic from going global. Foreign Affairs, 97, 118–129.
Buck, J. A. (2011). The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs, 20, 1402–1410. CrossRef
Carson, E. A., & Anderson, E. (2016). Prisoners in 2015. Bureau of Justice Statistics Bulletin. United States Department of Justice.
Patashnik, E. M., Gerber, A. A., & Dowling, C. M. (2017). Unhealthy politics: The battle over evidence-based medicine. Princeton: Princeton University Press. CrossRef
White, W. L. (1998). Slaying the dragon: The history of addiction treatment and recovery in America. Bloomington, IL: Chestnut Health Systems.
Humphreys, K. (2004). Circles of recovery: Self-help organisations for addictions. Cambridge, UK: Cambridge University Press.
Humphreys, K. (2017). How to deliver a more persuasive message regarding addiction as a medical disorder. Journal of Addiction Medicine, 11, 174–175. CrossRef
Humphreys, K., & Piot, P. (2012). Scientific evidence alone is not sufficient basis for health policy. British Medical Journal, 344, e1316. CrossRef
Forman, J. J. (2017). Locking up our own: Crime and punishment in Black America. New York: Macmillan.
Massing, M. (2000). The fix. Berkeley: University of California Press.
Babor, T. F., Caulkins, J., Fischer, B., Foxcroft, D., Humphreys, K., Medina-Mora, M., … Strang, J. S. (2018). Drug policy and the public good (2nd ed.). London: Oxford University Press.
Dagan, D., & Teles, S. (2016). Prison break why conservatives turned against mass incarceration. Oxford: Oxford University Press.
Gottlieb, S. (2017). Remarks from FDA Commissioner Scott Gottlieb, M. D., as prepared for oral testimony before the House Committee on Energy and Commerce Hearing, “Federal Efforts to Combat the Opioid Crisis: A Status Update on CARA and Other Initiatives”. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm582031.htm.
Kaplan, S. (2018, February 25). F.D.A. to expand medication-assisted therapy for opioid addicts. New York Times. https://www.nytimes.com/2018/02/25/science/fda-medication-assisted-therapy.html.
Waxman, O. (2017, October 26). As President Trump declares opioid emergency, here’s what to know about the history of ‘Just Say No’. Time. http://time.com/4999376/history-opioid-just-say-no/.
Phillips, K. (2018, February 27). Trump reportedly praised Singapore for executing drug dealers. Here’s how they’re killed. Washington Post. https://www.washingtonpost.com/news/worldviews/wp/2018/02/27/trump-reportedly-praised-singapore-for-executing-drug-dealers-heres-how-theyre-killed/?utm_term=.21034f0181b8.
Lopez, G. (2017, October 24). Under Trump and Sessions, federal prosecutors are ramping up the war on drugs. https://www.vox.com/policy-and-politics/2017/10/24/16534812/trump-sessions-war-on-drugs.
Darke, S., & Zador, D. (1996). Fatal heroin “overdose”: A review. Addiction, 91, 1765–1772. CrossRef
Sun, E. C., Dixit, A., Humphreys, K., Darnell, B., Baker, L. C., & Mackey, S. (2017). Association between concurrent use of prescription opioids and benzodiazepine with overdose: A retrospective analysis. British Medical Journal, 356, j760. CrossRef
Hall, W. D., & Strang, J. S. (2017). Alcohol problems need more attention in patients receiving long-term opioid substitution therapy. Lancet Psychiatry, 4, 265–266. CrossRef
McLellan, A. T., Luborsky, L., Woody, G. E., O’Brien, C. P., & Kron, R. (1981). Are the “addiction-related” problems of substance abusers really related? Journal of Nervous and Mental Disease, 169, 232–239. CrossRef
Mbaba, M., Brown, S. E., Wooditch, A., Kiss, M., Murphy, A., Kumari, S., … Springer, S. A. (2018). Prevalence, diagnosis, and treatment rates of mood disorders among opioid users under criminal justice supervision. Substance Use & Misuse, 53, 1519–1528.
Humphreys, K., Malenka, R., Knutson, B., & MacCoun, R. (2017). Brains, environments and policy responses to addiction. Science, 356, 1237–1238. CrossRef
Allen, B. (2015, August 16). When rehab might help an addict—But insurance won’t cover it. National Public Radio. https://www.npr.org/sections/health-shots/2015/08/16/430437514/when-rehab-might-help-an-addict-but-insurance-wont-cover-it.
Strang, J., McCambridge, J., Best, D., Beswick, T., Bearn, J., Rees, S., & Gossop, M. (2003). Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study. British Medical Journal, 326, 959–960.
Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007). Release from prison—A high risk of death for former inmates. New England Journal of Medicine, 356, 157–165.
Herman, D. B., & Mandiberg, J. M. (2010). Critical time intervention: Model description and implications for the significance of timing in social work interventions. Research on Social Work Practice, 20, 502–508. CrossRef
Green, T. C., Clarke, J., Brinkley-Rubinstein, L., Marshall, B. D. L., Alexander-Scott, N., Boss, R., & Rich, J. D. (2018, February 14). Post incarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2017.4614.
Carroll, K. M., & Weiss, R. D. (2017). The role of behavioral interventions in buprenorphine maintenance treatment: A review. American Journal of Psychiatry, 174, 738–747. CrossRef
Richardson, L., Wood, E., Li, K., & Kerr, T. (2010). Factors associated with employment among a cohort of injection drug users. Drug and Alcohol Review, 29, 293–300. CrossRef
Fiellin, D. A., Kleber, H., Trumble-Hejduk, J. G., McLellan, A. T., & Kosten, T. R. (2004). Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment, 27(2), 153–159. CrossRef
Alderks, C. (2017). Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities 2003–2015 (updated) (CBHSQ Report). https://www.samhsa.gov/data/sites/default/files/report_3192/ShortReport-3192.pdf. Accessed December 20, 2017.
Clemens-Cope, L. Epstein, M., & Kenney, G. M. (2017). Rapid growth in Medicaid spending on medications to treat opioid use disorder and overdose. Washington, DC: Urban Institute. https://www.urban.org/sites/default/files/publication/91521/2001386-rapid-growth-in-medicaid-spending-on-medications-to-treat-opioid-use-disorder-and-overdose_2.pdf.
World Health Organization. (2009). WHO guidelines for psychosocially assisted pharmacological treatment of persons dependent on opioids. Geneva, Switzerland: World Health Organization.
Amato, L., Davoli, M., Perucci, C. A., Ferri, M., Faggiano, F., & Mattick, R. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment, 28, 321–330. CrossRef
Barnett, P. (1999). The cost-effectiveness of methadone maintenance as a health care intervention. Addiction, 94, 479–488. CrossRef
Gunne, L. M., & Grönbladh, L. (1981). The Swedish methadone maintenance program: A controlled study. Drug and Alcohol Dependence, 7, 249–256. CrossRef
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., … Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. British Medical Journal, 357, j1550.
Basu, A., Paltiel, A. D., & Pollack, H. A. (2008). Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Economics, 17, 927–946. CrossRef
Adi, Y., Juarez-Garcia, A., Wang, D., Jowett, S., Frew, E., Day, E., … Burls, A. (2007). Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation. Health Technology Assessment, 11, 1–85.
Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23, 63–75. CrossRef
Krupitsky, E., Zvartau, E., Blokhina, E., Verbitskaya, E., Wahlgren, V., Tsoy-Podosenin, M., … Woody, G. E. (2012). Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Archives of General Psychiatry, 69, 973–981.
Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., … O’Brien, C. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine, 374, 1232–1242.
Tanum, L., Solli, K. K., Latif, Z., Benth, J. S., Opheim, A., Sharma-Haase, K., … Kune, N. (2017). Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence. JAMA Psychiatry, 74, 1197–1205.
Prendergast, M. L., Podus, D., Chang, E., & Urada, D. (2002). The effectiveness of drug abuse treatment: A meta-analysis of comparison group studies. Drug and Alcohol Dependence, 67, 53–73. CrossRef
Mayet, S., Farrell, M., Ferri, M., Amato, L., & Davoli, M. (2005, January 25). Psychosocial treatment for opiate abuse and dependence. Cochrane Database Systematic Review, 1, CD004330.
Butzin, C. A., Martin, S. S., & Inciardi, J. A. (2005). Treatment during transition from prison to community and subsequent illicit drug use. Journal of Substance Abuse Treatment, 28, 351–358. CrossRef
Vanderplasschen, W., Colpaert, K., Autrique, M., Rapp, R., Pearce, A., Broekaert, E., & Vandevelde, S. (2013, January 15). Therapeutic communities for addictions: A review of their effectiveness from a recovery-oriented perspective. Scientific World Journal, 2013, 1–22.
Babor, T. F., Caulkins, J., Edwards, G. E., Fischer, B., Foxcroft, D., Humphreys, K., … Strang, J. S. (2010). Drug policy and the public good. New York: Oxford University Press.
Welsh, W. N., Zajac, G., & Bucklen, K. B. (2014). For whom does prison-based drug treatment work? Results from a randomized experiment. Journal of Experimental Criminology, 10, 151–177. CrossRef
D’Aunno, T., & Pollack, H. A. (2002). Changes in methadone treatment practices: Results from a national panel study, 1988–2000. Journal of the American Medical Association, 288, 850–856. CrossRef
White, W., Galanter, M., Humphreys, K., & Kelly, J. (2016). The paucity of attention to Narcotics Anonymous in current public, professional and policy responses to rising opioid addiction. Alcoholism Treatment Quarterly, 34, 437–462. CrossRef
Jason, L. A., Olson, B. D., Ferrari, J. R., & Lo Sasso, L. T. (2006). Communal housing settings enhance substance abuse recovery. American Journal of Public Health, 96, 1727–1729. CrossRef
Heimer, R. (1998). Can syringe exchange serve as a conduit to substance abuse treatment? Journal of Substance Abuse Treatment, 15, 183–191. CrossRef
Pollack, H. A. (2001). Cost-effectiveness of harm reduction in preventing Hepatitis C among injection drug users. Medical Decision Making, 21, 357–367. CrossRef
Groseclose, S. L., Weinstein, B., Jones, T. S., Valleroy, L. A., Fehrs, L. J., & Kassler, W. (1995). Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officer, Connecticut, 1992–1993. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 10, 82–89. CrossRef
Humphreys, K. (2015). An overdose rescue drug goes mainstream. Health Affairs, 34, 1624–1627. CrossRef
Baca, C. T., & Grant, K. J. (2005). Take-home naloxone to reduce heroin death. Addiction, 100, 1823–1831. CrossRef
Strang, J., Darke, S., Hall, W., Farrell, M., & Ali, R. (1996). Heroin overdose: The case for take-home naloxone. British Medical Journal, 312, 1435–1436. CrossRef
Darke, S., & Hall, W. (1997). The distribution of naloxone to heroin users. Addiction, 92, 1195–1199. CrossRef
McDonald, R., & Strang, J. S. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction, 111, 1177–1187. CrossRef
Walley, A. Y., Xuan, Z., Hackman, H. H., et al. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. British Medical Journal, 346, f174.
Williams, A. V., Marsden, J., & Strang, J. (2014). Training family members to manage heroin overdose and administer naloxone: Randomized trial of effects on knowledge and attitudes. Addiction, 109, 250–259. CrossRef
Bashir, K., King, M., & Ashworth, M. (1994). Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. British Journal of General Practice, 44, 408–412.
Cormack, M. A., Sweeney, K. G., Hughes-Jones, H., & Foot, G. A. (1994). Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice. British Journal of General Practice, 44, 5–8.
Tannenbaum, C., Martin, P., & Tamblin, R. (2014). Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: The EMPOWER cluster randomized trial. JAMA Internal Medicine, 174, 890–898. CrossRef
Marsden, J., Stillwell, G., Barlow, H., Boys, A., Taylor, C., Hunt, N., & Farrell, M. (2005). An evaluation of a brief motivational intervention among young ecstasy and cocaine users: No effect on substance and alcohol use outcomes. Addiction, 101, 1014–1026.
Baker, A., Lewin, T., Reichler, H., Clancy, R., Carr, V., Garrett, R., … Terry, M. (2002). Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction, 97, 1329–1337.
Humphreys, K. (2017). Avoiding globalisation of the prescription opioid epidemic. The Lancet, 390, 437–439. CrossRef
Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States. Morbidity and Mortality Weekly Report, 65, 1–49.
Lembke, A., Humphreys, K., & Newmark, J. (2016). Weighing the risks and benefits of chronic opioid therapy. American Family Physician, 93, 982–990.
Morris, L. A., & Halperin, J. A. (1979). Effects of written drug information on patient knowledge and compliance: A literature review. American Journal of Public Health, 69, 47–52. CrossRef
Peveler, R., George, C., Kinmonth, A. L., Campbell, M., & Thompson, C. (1999). Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: Randomised controlled trial. British Medical Journal (Clinical Research Ed.), 319, 612–615. CrossRef
Roughead, E. E., Semple, S. J., & Vitry, A. I. (2005). Pharmaceutical care services: A systematic review of published studies, 1990 to 2003, examining effectiveness in improving patient outcomes. International Journal of Pharmacy Practice, 13, 53–70. CrossRef
Schnipper, J. L., Kirwin, J. L., Cotugno, M. C., Wahlstrom, S. A., Brown, B. A., Tarvin, E., … Bates, D. W. (2006). Role of pharmacist counseling in preventing adverse drug events after hospitalization. Archives of Internal Medicine, 166, 565–571.
Christensen, D. B., & Farris, K. B. (2006). Pharmaceutical care in community pharmacies: Practice and research in the US. The Annals of Pharmacotherapy, 40, 1400–1406. CrossRef
Betses, M., & Brennan, T. (2013). Abusive prescribing of controlled substances—A pharmacy view. New England Journal of Medicine, 369, 989–991. CrossRef
Sacarny, A., Yokum, D., Finkelstein, A., & Agrawal, S. (2016). Medicare letters to curb overprescribing of controlled substances had no detectable effect on providers. Health Affairs, 35, 471–479. CrossRef
Aaserud, M., Dahlgren, A. T., Kosters, J. P., Oxman, A. D., Ramsay, C., & Sturm, H. (2006). Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies. The Cochrane Database of Systematic Reviews, 2, CD005979.
Cicero, T. J., Inciardi, J. A., Adams, E. H., Geller, A., Senay, E. C., Woody, G. E., & Munoz, A. (2005). Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994–2004. Pharmacoepidemiology and Drug Safety, 14, 851–859.
Gomes, T., Mamdani, M. M., Dhalla, I. A., Cornish, S., Paterson, J. M., & Juurlink, D. N. (2014). The burden of premature opioid-related mortality. Addiction, 109, 1482–1488. CrossRef
Fischer, B., & Keates, A. (2012). ‘Opioid drought’, Canadian-style? Potential implications of the ‘natural experiment’ of delisting Oxycontin in Canada. The International Journal on Drug Policy, 23, 495–497. CrossRef
Fischer, B., Jones, W., & Rehm, J. (2014). Trends and changes in prescription opioid analgesic dispensing in Canada 2005–2012: An update with a focus on recent interventions. BMC Health Services Research, 14, 90. CrossRef
Faul, M., Bohm, M., & Alexander, C. (2017). Methadone prescribing and overdose an the association with Medicaid preferred drug list policies—United States, 2007–2014. Morbidity and Mortality Weekly Report, 66, 320–323. CrossRef
Hall, A. J., Logan, J. E., Toblin, R. L., Kaplan, J. A., Kraner, J. C., Bixler, D., … Paulozzi, L. J. (2008). Patterns of abuse among unintentional pharmaceutical overdose fatalities. Journal American Medical Association, 300, 2613–2620.
Roberts, A. W., & Skinner, A. C. (2014). Assessing the present state and potential of Medicaid controlled substance lock-in programs. Journal of Managed Care & Specialty Pharmacy, 20(5), 439–446. CrossRef
Katz, N. P., Brennan, M. J., Freedman, J. D., Birnbaum, H., Gilmore, G. P., Jay, D., … White, A. G. (2013). Prescription opioid abuse: Challenges and opportunities for payers. American Journal of Managed Care, 19, 295–302.
Franklin, G., Sabel, S., Jones, C. M., Mai, J., Baumgartner, C., Banta-Green, C. J., … Tauben, D. J. (2015). A comprehensive approach to address the prescription opioid epidemic in Washington State: Milestones and lessons learned. American Journal of Public Health, 105, 463–469.
Brennan, N., & Mattick, K. (2013). A systematic review of educational interventions to change behaviour of prescribers in hospital settings, with a particular emphasis on new prescribers. British Journal of Clinical Pharmacology, 75, 359–372. CrossRef
Franklin, G. M., Mai, J., Turner, J., Sullivan, M., Wickizer, T., & Fulton-Kehoe, D. (2012). Bending the prescription opioid dosing and mortality curves: Impact of the Washington state opioid dosing guideline. American Journal of Industrial Medicine, 55, 325–331. CrossRef
Pimlott, N. J., Hux, J. E., Wilson, L. M., Kahan, M., Li, C., & Rosser, W. W. (2003). Educating physicians to reduce benzodiazepine use by elderly patients: A randomized controlled trial. CMAJ: Canadian Medical Association Journal [Journal De L’Association Medicale Canadienne], 168, 835–839.
Hooper, S., Bruno, R., Sharpe, M., & Tahmindjis, A. (2009). Alprazolam prescribing in tasmania: A two-fold intervention designed to reduce inappropriate prescribing and concomitant opiate prescription. Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists, 17, 300–305. CrossRef
Kahan, M., Gomes, T., Juurlink, D. N., Manno, M., Wilson, L., Mailis-Gagnon, A., … Mamdani, M. M. (2013). Effect of a course-based intervention and effect of medical regulation on physicians’ opioid prescribing. Canadian Family Physician, 59, 231–239.
Parish, C. L., Pereyra, M. R., Pollack, H. A., Cardenas, G., Castellon, P. C., Abel, S. N., … Metsch, L. R. (2015). Screening for substance misuse in the dental care setting: Findings from a nationally representative survey of dentists. Addiction, 110, 1516–1523.
Saunders, K., Shortreed, S., Thielke, S., Turner, J. A., LeResche, L., Beck, R., & Von Korff, M. (2015). Evaluation of health plan interventions to influence chronic opioid therapy prescribing. Clinical Journal of Pain. https://doi.org/10.1097/ajp.0000000000000159.
Victorri-Vigneau, C., Basset, G., Bourin, M., & Jolliet, P. (2003). Impacts of the new flunitrazepam regulations on the consumption of hypnotics [Impacts de la nouvelle reglementation du flunitrazepam sur la consommation d’hypnotiques] . Therapie, 58(5), 425–430.
Jonasson, U., & Jonasson, B. (2004). Restrictions on the prescribing of dextropropoxyphene (DXP)-effects on sales and cases of fatal poisoning. Stockholm, Sweden: Swedish National Board of Forensic Medicine and Medical Products Agency.
Seago, S., Hayek, A., Pruszynski, J., & Newman, M. G. (2016). Change in prescription habits after federal rescheduling of hydrocodone combination products. Baylor University Medical Center Proceedings, 29, 268–270. CrossRef
Jones, C. M., Lurie, P. G., & Throckmorton, D. C. (2016). Effect of US Drug Enforcement Administration’s rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Internal Medicine, 176, 399–402. CrossRef
Furlan, A. D., MacDougall, P., Pellerin, D., Shaw, K., Spitzig, D., Wilson, G., & Wright, J. (2014). Overview of four prescription monitoring/review programs in Canada. Pain Research & Management, 19, 102–106.
Katz, N., Houle, B., Fernandez, K., Kreiner, P., Thomas, C., Kim, M., … Brushwood, D. (2008). Update on prescription monitoring in clinical practice: A survey study of prescription monitoring program administrators. Pain Medicine, 9, 587–594.
Pardo, B. (2017). Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction, 112, 1773–1783. CrossRef
Moyo, P., Simoni-Wastila, L., Griffi, B. A., Harrington, D., Alexander, G. C., & Palumbo, F. (2017). Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 U.S. States. Addiction, 112, 1784–1796. CrossRef
Baehren, D. F., Marco, C. A., Droz, D. E., Sinha, S., Callan, E. M., & Akpunonu, P. (2010). A statewide prescription monitoring program affects emergency department prescribing behaviors. Annals of Emergency Medicine, 56, 19–23. CrossRef
Dormuth, C. R., Miller, T. A., Huang, A., Mamdani, M. M., & Juurlink, D. N. (2012). Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. Canadian Medical Association Journal, 184, E852–E856. CrossRef
Fishman, S. M., Papazian, J. S., Gonzalez, S., Riches, P. S., & Gilson, A. (2004). Regulating opioid prescribing through prescription monitoring programs: Balancing drug diversion and treatment of pain. Pain Medicine, 5(3), 309–324. CrossRef
Gilson, A. M., Fishman, S. M., Wilsey, B. L., Casamalhuapa, C., & Baxi, H. (2012). Time series analysis of California’s prescription monitoring program: Impact on prescribing and multiple provider episodes. Journal of Pain, 13, 103–111. CrossRef
Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016). Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Affairs, 35, 1324–1332. CrossRef
Paulozzi, L., Kilbourne, E. M., & Desai, H. A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine, 12, 747–754. CrossRef
Reifler, L. M., Droz, D., Bailey, J. E., Schnoll, S. H., Fant, R., Dart, R. C., & Bucher Bartelson, B. (2012). Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Medicine, 13, 434–442.
Gugelmann, H. M., & Perrone, J. (2011). Can prescription drug monitoring programs help limit opioid abuse? The Journal of the American Medical Association, 306, 2258–2259. CrossRef
Simoni-Wastila, L., & Yang, H. K. (2006). Psychoactive drug abuse in older adults. The American Journal of Geriatric Pharmacotherapy, 4, 380–394. CrossRef
Fischer, B., Lusted, A., Roerecke, M., Taylor, B., & Rehm, J. (2012). The prevalence of mental health and pain symptoms in general population samples reporting non-medical use of prescription opioids: A systematic review and meta-analysis. Journal of Pain, 13, 1029–1044. CrossRef
Albert, S., Brason, F. W., Sanford, C. K., Dasgupta, N., Graham, J., & Lovette, B. (2011). Project Lazarus: Community-based overdose prevention in rural North Carolina. Pain Medicine (Malden, Mass.), 12(Suppl. 2), S77–S85.
Stewart, H., Malinowski, A., Ochs, L., Jaramillo, J., McCall, K., 3rd, & Sullivan, M. (2015). Inside Maine’s medicine cabinet: Findings from the drug enforcement administration’s medication take-back events. American Journal of Public Health, 105(1), e65–e71. CrossRef
Katz, N., Adams, E. H., Chilcoat, H., Colucci, R., Comer, S. D., Goliber, P., … Weiss, R. (2007). Challenges in the development of prescription opioid abuse-deterrent formulations. Clinical Journal of Pain, 23, 648–660.
Romach, M. K., Schoedel, K. A., & Sellers, E. M. (2013). Update on tamper-resistant drug formulations. Drug and Alcohol Dependence, 130, 13–23. CrossRef
Mastropietro, D. J., & Omidian, H. (2013). Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Development and Industrial Pharmacy, 39, 611–624. CrossRef
Comer, S. D., Sullivan, M. A., Vosburg, S. K., Manubay, J., Amass, L., Cooper, Z. D., … Kleber, H. D. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction, 105, 709–718.
Lavonas, E. J., Severtson, S. G., Martinez, E. M., Bucher-Bartelson, B., Le Lait, M. C., Green, J. L., … Dart, R. C. (2014). Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment, 47, 27–34.
Severtson, S. G., Ellis, M. S., Kurtz, S. P., Rosenblum, A., Cicero, T. J., Parrino, M. W., … Dart, R. C. (2016). Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug and Alcohol Dependence, 168, 219–229.
Bannwarth, B. (2012). Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs, 72, 1713–1723. CrossRef
Becker, W. C., & Fiellin, D. A. (2017). Abuse-deterrent opioid formulations—Putting the potential benefits into perspective. New England Journal of Medicine, 376, 2015–2103. CrossRef
Cicero, T. J., & Ellis, M. S. (2015). Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin. JAMA Psychiatry, 72, 424–429. CrossRef
Lourenco, L. M., Matthews, M., & Jamison, R. N. (2013). Abuse-deterrent and tamper-resistant opioids: How valuable are novel formulations in thwarting non-medical use? Expert Opinion on Drug Delivery, 10, 229–240. CrossRef
Butler, S. F., Cassidy, T. A., Chilcoat, H., Black, R. A., Landau, C., Budman, S. H., & Coplan, P. M. (2013). Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. The Journal of Pain, 14, 351–358.
Cicero, T. J., Ellis, M. S., & Surratt, H. L. (2012). Effect of abuse-deterrent formulation of OxyContin. The New England Journal of Medicine, 367(2), 187–189. CrossRef
Coplan, P. M., Kale, H., Sandstrom, L., Landau, C., & Chilcoat, H. D. (2013). Changes in oxycodone and heroin exposures in the national poison data system after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiology and Drug Safety, 22, 1274–1282. CrossRef
Coplan, P. M., Chilcoat, H. D., Butler, S. F., Sellers, E. M., Kadakia, A., Karikrishnan, V., … Dart, R. C. (2016). The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid-abuse related outcomes in the postmarketing setting. Clinical Pharmacology & Therapeutics, 100, 275–286.
Sessler, N. E., Downing, J. M., Kale, H., Chilcoat, H. D., Baumgartner, T. F., & Coplan, P. M. (2014). Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiology and Drug Safety, 23, 1238–1246. CrossRef
Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B., & Green, J. L. (2015). Trends in opioid analgesic abuse and mortality in the United States. The New England Journal of Medicine, 372(3), 241–248.
Strang, J., & Sheridan, J. (1997). Heroin prescribing in the “British system” of the mid 1990s: Data from the 1995 national survey of community pharmacies in England and Wales. Drug and Alcohol Review, 16, 7–16. CrossRef
Surratt, H. L., O’Grady, C., Kurtz, S. P., Stivers, Y., Cicero, T. J., Dart, R. C., & Chen, M. (2014). Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiology and Drug Safety, 23, 314–320.
Johnson, H., Paulozzi, L., Porucznik, C., Mack, K., & Herter, B. (2014). Decline in drug overdose deaths after state policy changes—Florida, 2010–2012. MMWR: Morbidity and Mortality Weekly Report, 63, 569–574.
Brennan, T. A., Rothman, D. J., Blank, L., Blumenthal, D., Chimonas, S. C., Cohen, J. J., … Smelser, N. (2006). Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. The Journal of the American Medical Association, 295, 429–433.
Kassirer, J. P. (2005). On the take: How medicine’s complicity with big business can endanger your health. New York: Oxford University Press. CrossRef
Meier, B. (2007). In guilty plea, Oxycontin maker to pay $600 million. New York Times. Available at http://www.nytimes.com/2007/05/10/business/11drug-web.html.
- How Should the United States Respond to the Opioid Addiction and Overdose Epidemic?
Harold A. Pollack
- Chapter 10